PLUVICTO®▼ (lutetium [177Lu] vipivotide tetraxetan) [1]
This page/content is for Great Britain healthcare professionals only.
Pluvicto® is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.2
Pluvicto®▼
The first and only licensed PSMA-targeted radioligand therapy (RLT) that, when used alongside BSoC, significantly extends survival† and maintains quality of life for longer,‡ vs BSoC alone, in eligible PSMA-positive mCRPC patients.1,2